Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
N06BX02
CAS registry number (Chemical Abstracts Service)
0001098-97-1
Chemical Formula
C16-H20-N2-O4-S2
Molecular Weight
368
Therapeutic Category
Nootropic
Chemical Name
4-Pyridinemethanol, 3,3'-[dithiobis(methylene)]bis[5-hydroxy-6-methyl-
Foreign Names
- Pyritinolum (Latin)
- Pyritinol (German)
- Pyritinol (French)
- Piritinol (Spanish)
Generic Names
- Piritinolo (OS: DCIT)
- Pyritinol (OS: BAN, DCF, USAN)
- Pyritioxine (IS)
- Pyritioxine Hydrochloride (OS: JAN)
Brand Names
- Bonifen
Merck, Venezuela - Encefabol
Merck, Colombia - Encepan
Interbat, Indonesia - Encephabol
Merck, Austria; Merck, Luxembourg; Merck, Mexico - Fitina
Vargas, Venezuela - Piritinol L.CH.
Chile, Chile - Acon
Roemmers, Venezuela - Bonitrop
Cofasa, Venezuela - Cerbon-6
Confar, Portugal - Encefabol
Mepro, Chile; Merck, Ecuador; Merck, Peru - Encephabol
Merck, United Arab Emirates; Merck, Austria; Merck, Bahrain; Merck, Cyprus; Merck, Czech Republic; Merck, Germany; Merck, Egypt; Merck, Hong Kong; Merck, Indonesia; Merck, India; Merck, Iraq; Merck, Iran; Merck, Jordan; Merck, Kuwait; Merck, Luxembourg; Merck, Mexico; Merck, Oman; Merck, Philippines; Merck, Qatar; Merck, Saudi Arabia; Merck, Sudan; Merck, Thailand; Merck, Yemen; Merck KGaA, Latvia; Merck KGaA, Romania; Merck Serono, South Africa; MSD, Lebanon; Nycomed, Georgia; Nycomed, Russian Federation - Enerbol
Ikapharmindo, Indonesia; Pliva, Czech Republic; Pliva, Poland; Pliva, Romania - Italram
Italpharma, Ecuador - Piritinol Diclorhidrato
Mintlab, Chile - Piritinol
Terapia, Romania
International Drug Name Search
Glossary
BAN | British Approved Name |
DCF | Dénomination Commune Française |
DCIT | Denominazione Comune Italiana |
IS | Inofficial Synonym |
JAN | Japanese Accepted Name |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
Click for further information on drug naming conventions and International Nonproprietary Names.
No comments:
Post a Comment